AI startup Lila Sciences is closing a $235 million Series A funding round to develop scientific superintelligence that integrates artificial intelligence deeply into laboratory research. The company aims to fundamentally transform drug discovery and development by automating experimental science and data analysis. The capital infusion underscores growing investor enthusiasm for AI platforms targeting the biotech R&D pipeline and promises accelerated innovation.